Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy

Cited by papers we hold 4

• Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy · 2023
  Corrected
• Emerging agents and regimens for AML · 2021
  No notice
• Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies · 2020
  No notice
• Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling · 2019
  Corrected

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.